{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:19:14Z","timestamp":1778739554369,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.euf.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:51:56Z","timestamp":1769143916000},"page":"162-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Future of Non\u2013muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5263-1398","authenticated-orcid":false,"given":"Pierre-Etienne","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.01.005_b0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2025.03.023","article-title":"Urine tumor DNA to stratify the risk of recurrence in patients treated with atezolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive non\u2013muscle-invasive bladder cancer","volume":"88","author":"St-Laurent","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.005_b0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the Xpert Bladder Cancer Monitor urinary biomarker test for guiding cystoscopy in high-grade non\u2013muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.005_b0015","doi-asserted-by":"crossref","unstructured":"BinHumaid FS, Goel A, Gordon NS, et al. Circulating tumour DNA positivity predicts shorter survival for patients with high-grade pT1 urothelial bladder carcinoma. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.007.","DOI":"10.1016\/j.eururo.2025.11.007"},{"key":"10.1016\/j.euf.2026.01.005_b0020","doi-asserted-by":"crossref","unstructured":"Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, et al. Development and international evaluation of an artificial intelligence-based model (PROGRxN-BCa) Using the World Health Organization 2004\/2022 grading system to predict progression risk and improve substratification for non\u2013muscle-invasive bladder cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4145.","DOI":"10.1016\/j.eururo.2025.09.4145"},{"key":"10.1016\/j.euf.2026.01.005_b0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2025.05.035","volume":"88","author":"Chang","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.005_b0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41746-024-01088-7","article-title":"Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI","volume":"7","author":"Kwong","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.euf.2026.01.005_b0035","doi-asserted-by":"crossref","unstructured":"Khene ZE, Bensalah K, Roupr\u00eat M. Artificial intelligence for risk prediction in non\u2013muscle-invasive bladder cancer: from complexity to clinical clarity. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.010.","DOI":"10.1016\/j.eururo.2025.11.010"},{"key":"10.1016\/j.euf.2026.01.005_b0040","doi-asserted-by":"crossref","unstructured":"Meghani K, Yu Y, Frydenlund N, et al. Genomic and transcriptomic profiling of high-risk bladder cancer reveals diverse molecular and microenvironment ecosystems. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4138.","DOI":"10.1016\/j.eururo.2025.09.4138"},{"key":"10.1016\/j.euf.2026.01.005_b0045","doi-asserted-by":"crossref","unstructured":"McConkey DJ, Barb JJ, Smith AK, Neugent ML. The bladder tumor microenvironment is a dynamic ecosystem: how microbes, immunity, and cancer converge. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.009.","DOI":"10.1016\/j.eururo.2025.11.009"},{"key":"10.1016\/j.euf.2026.01.005_b0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eururo.2025.04.015","article-title":"Follow-up for non\u2013muscle-invasive bladder cancer: should the guidelines be adapted?","volume":"88","author":"Witjes","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:59:38Z","timestamp":1773745178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2405456926000040"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Non\u2013muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}